Vermillion Stock Price, Forecast & Analysis (NASDAQ:VRML)

Vermillion trades on the NASDAQ under the ticker symbol "VRML."

Vermillion, Inc. (NASDAQ:VRML) announced its earnings results on Thursday, August, 8th. The company reported ($0.06) earnings per share for the quarter. The company had revenue of $1.14 million for the quarter. Vermillion had a negative net margin of 370.83% and a negative return on equity of 159.48%. View Vermillion's Earnings History.

Vermillion is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Vermillion.

Media coverage about VRML stock has trended very negative on Tuesday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vermillion earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Vermillion.

Vermillion saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 2,520,000 shares, an increase of 8.6% from the September 15th total of 2,320,000 shares. Based on an average daily volume of 270,500 shares, the short-interest ratio is presently 9.3 days. Approximately 4.9% of the shares of the stock are sold short. View Vermillion's Current Options Chain.

Some companies that are related to Vermillion include Nymox Pharmaceutical (NYMX), ImmuCell (ICCC), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), GeneNews (GNWSF), Arca Biopharma (ABIO), Achieve Life Sciences (ACHV), Akers Biosciences (AKER), BG Medicine (BGMD), Fluoropharma Medical (FPMI) and Response Genetics (RGDXQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Vermillion investors own include CombiMatrix (CBMX), TrovaGene (TROV), NovaBay Pharmaceuticals (NBY), Accelerate Diagnostics (AXDX), Himax Technologies (HIMX), Charter Communications (CHTR), Opko Health (OPK), Genworth Financial (GNW), Magnachip Semiconductor (MX) and BIOLASE (BIOL).

Vermillion's stock is owned by a number of of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (0.35%). Company insiders that own Vermillion stock include David Schreiber, Jack W Schuler, James T Lafrance, Robert Harry Beechey and Valerie Barber Palmieri. View Institutional Ownership Trends for Vermillion.

VRML stock was purchased by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. Company insiders that have bought Vermillion stock in the last two years include Jack W Schuler, Robert Harry Beechey and Valerie Barber Palmieri. View Insider Buying and Selling for Vermillion.

Shares of VRML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VRML stock can currently be purchased for approximately $0.64.

Vermillion has a market capitalization of $62.20 million and generates $3.05 million in revenue each year. Vermillion employs 43 workers across the globe.View Additional Information About Vermillion.

The official website for Vermillion is http://www.vermillion.com/.

Vermillion's mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company can be reached via phone at 512-519-0400 or via email at [email protected]